JP2023544724A5 - - Google Patents
Info
- Publication number
- JP2023544724A5 JP2023544724A5 JP2023519831A JP2023519831A JP2023544724A5 JP 2023544724 A5 JP2023544724 A5 JP 2023544724A5 JP 2023519831 A JP2023519831 A JP 2023519831A JP 2023519831 A JP2023519831 A JP 2023519831A JP 2023544724 A5 JP2023544724 A5 JP 2023544724A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- pharmaceutical composition
- use according
- substituted
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086830P | 2020-10-02 | 2020-10-02 | |
| US63/086,830 | 2020-10-02 | ||
| US202063114769P | 2020-11-17 | 2020-11-17 | |
| US63/114,769 | 2020-11-17 | ||
| US202163241891P | 2021-09-08 | 2021-09-08 | |
| US63/241,891 | 2021-09-08 | ||
| PCT/EP2021/077057 WO2022069690A2 (en) | 2020-10-02 | 2021-10-01 | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023544724A JP2023544724A (ja) | 2023-10-25 |
| JP2023544724A5 true JP2023544724A5 (enExample) | 2024-07-29 |
Family
ID=78080292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519831A Pending JP2023544724A (ja) | 2020-10-02 | 2021-10-01 | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230355583A1 (enExample) |
| EP (1) | EP4221682A2 (enExample) |
| JP (1) | JP2023544724A (enExample) |
| KR (1) | KR20230079351A (enExample) |
| AU (1) | AU2021354006A1 (enExample) |
| CA (1) | CA3194558A1 (enExample) |
| WO (1) | WO2022069690A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス， インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| HRP20220797T1 (hr) | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| MX2024008691A (es) * | 2022-01-14 | 2024-07-19 | Cybin Irl Ltd | Composiciones y metodos de triptamina. |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20250205198A1 (en) * | 2022-03-31 | 2025-06-26 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| AU2023361184A1 (en) * | 2022-10-13 | 2025-04-24 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| EP4601638A2 (en) * | 2022-10-14 | 2025-08-20 | ATAI Therapeutics, Inc. | Acetal, ketal, and hemiaminal analogs of psilocin, processes for the preparation thereof, and methods of use |
| US12280216B2 (en) | 2023-02-01 | 2025-04-22 | Thomas E. Garrison | Mixtures including nitrous oxide |
| US11980717B1 (en) * | 2023-02-01 | 2024-05-14 | Thomas E. Garrison | Mixtures including nitrous oxide |
| EP4739303A2 (en) * | 2023-07-03 | 2026-05-13 | EmpathBio, Inc. | Mdma enantiomer compositions and methods for modulating aggression response |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| CA2682432C (en) * | 2007-03-30 | 2017-06-06 | Duke University | Device and method for delivery of a medicament |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| HUE066828T2 (hu) * | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
-
2021
- 2021-10-01 EP EP21786852.0A patent/EP4221682A2/en active Pending
- 2021-10-01 US US18/027,810 patent/US20230355583A1/en active Pending
- 2021-10-01 AU AU2021354006A patent/AU2021354006A1/en active Pending
- 2021-10-01 WO PCT/EP2021/077057 patent/WO2022069690A2/en not_active Ceased
- 2021-10-01 CA CA3194558A patent/CA3194558A1/en active Pending
- 2021-10-01 KR KR1020237007858A patent/KR20230079351A/ko active Pending
- 2021-10-01 JP JP2023519831A patent/JP2023544724A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023544724A (ja) | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム | |
| CN102264703B (zh) | 作为β2肾上腺素受体促效剂的5-(2-{[6-(2,2-二氟-2-苯基乙氧基)己基]氨基}-1-羟乙基)-8-羟基喹啉-2(1H)-酮的甲磺酸盐 | |
| ES2610425T3 (es) | Composiciones farmacéuticas que comprenden carbamatos de alcohol perilílico | |
| AU2022342266B2 (en) | Combination drug therapies | |
| JP2001513492A (ja) | 生物活性巨大分子を含む水性エアゾール製剤及び該エアゾールの製造方法 | |
| CN1649588A (zh) | 基于抗胆碱能药物及pde－iv抑制剂的新颖药物组合物 | |
| KR20240013170A (ko) | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 | |
| WO2023186963A1 (en) | Combination of nitrous oxide and 5-ht2a receptor agonists | |
| RU2008124833A (ru) | Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций | |
| JP2025510942A5 (enExample) | ||
| TW200536533A (en) | Organic compounds | |
| TW201031408A (en) | Novel methods | |
| JP2025510944A5 (enExample) | ||
| JP2005505560A (ja) | 三環系５，６−ジヒドロ−９Ｈ−ピラゾロ（３，４−ｃ）−１，２，４−トリアゾロ（４，３−アルファ）ピリジンを含む吸入組成物 | |
| JP2011518859A5 (enExample) | ||
| KR20240134951A (ko) | 트립타민 조성물 및 방법 | |
| US20230100890A1 (en) | Use of combined inhalant cannabinoid therapy in the treatment of migraine | |
| TW200800141A (en) | HFC solution formulations containing salbutamol hydrochloride or salbutamol citrate | |
| EA012583B1 (ru) | КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ | |
| US20210046258A1 (en) | Method and apparatus for producing fine concentrated aerosol | |
| US20250205198A1 (en) | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods | |
| TW200835490A (en) | Novel substituted piperidyl-propane-thiols | |
| AU2023331937A1 (en) | Tryptamine compounds, compositions, and methods of use | |
| JP2025500344A (ja) | 睡眠時無呼吸の治療のためのα２－アドレナリン受容体サブタイプＣ（アルファ－２Ｃ）アンタゴニストとノルエピネフリン再取込み阻害薬との組合せ | |
| HK40114784A (en) | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA |